A detailed history of David Einhorn (Greenlight Capital Inc) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Greenlight Capital Inc holds 588,410 shares of GANX stock, worth $935,571. This represents 0.1% of its overall portfolio holdings.

Number of Shares
588,410
Previous 546,560 7.66%
Holding current value
$935,571
Previous $2.45 Million 21.41%
% of portfolio
0.1%
Previous 0.12%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$2.07 - $3.4 $86,629 - $142,290
41,850 Added 7.66%
588,410 $1.92 Million
Q1 2021

May 17, 2021

BUY
$11.2 - $14.92 $6.12 Million - $8.15 Million
546,560 New
546,560 $8.16 Million

Others Institutions Holding GANX

About Gain Therapeutics, Inc.


  • Ticker GANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,883,400
  • Market Cap $18.9M
  • Description
  • Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...
More about GANX
Track David Einhorn's Portfolio

Track David Einhorn Portfolio

Follow David Einhorn (Greenlight Capital Inc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Greenlight Capital Inc, based on Form 13F filings with the SEC.

News

Stay updated on Greenlight Capital Inc and David Einhorn with notifications on news.